Dornase Alfa as a Potential Treatment Option for SARS-CoV-2: In Vitro Insights

The potential use of dornase alfa (DA) for managing severe acute respiratory syndrome coronavirus 2 infection has been a topic of frequent discussion; however, its underlying mechanism of effectiveness remains insufficiently explored. By shedding light on the mechanisms involved, this research endeavors to contribute to the broader understanding of DA's suitability as a potential treatment option for SARS-CoV-2 infection. In this study, the effects of DA on SARS-CoV-2 were investigated to determine the change in the level of viral cytotoxicity, viral RNA fragmentation, spike blockage, in vitro Th1/Th2 cytokine ratio of viral peptide stimulated lymphocytes and netosis Neutrophil extracellular traps formation. The analysis demonstrated that DA decreased the viral cytotoxicity at 30U (p